Atreca Inc BCEL

Alternate Symbol(s): COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

PINL:BCEL - Post by User

Atreca Inc

Bullboard Posts

Post by wildkydon Oct 04, 2009 10:53am

439 Views

Post# 16360786

imagine

Using the values of the 43 meter hole and pretending it was a cube you would get 79507 cu. meters of rock.
(43 x 43 x43).
Multiply that by 2.5 (approx. density) and you get 198767 tonnes of rock.
Now if you plug the grades into the casey calculator you get $758922 /tonne. (calculation below)
Now let's multiply 198767 tonnes by 758922 and you get 150,849,028,635 or about $150 billion.
With 75% of the project that would net about $113 billion if fully realized.
If we are credited with 10% of that value that would be $11.3 billion.
Divide that by 85 million outstanding shares and you get a value of $132/share.
I'm holding...
- Wildkyd